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Salicylic acid (SAL) may impact Staphylococcus aureus virulence by activating the sigB operon (rsbU-V-W-
sigB), thus leading to reductions in alpha-toxin production and decreased fibronectin binding (L. I. Kupfer-
wasser et al., J. Clin. Investig. 112:222–233, 2003). As these prior studies were performed in strain RN6390 (an
rsbUmutant) and its rsbU-repaired variant, SH1000, the current investigation was designed to determine if the
SAL effect occurs via rsbU- and/or rsbV-dependent pathways in an rsbU-intact S. aureus strain (FDA486). We
thus quantified the transcription from two sigB-dependent promoters (asp23 and sarA P3) in FDA486 in
response to SAL exposure in vitro, using isogenic single-knockout constructs of rsbU, rsbV, or rsbW and a green
fluorescent protein reporter system. SAL induced sarA P3 and asp23 promoter activities in a dose-dependent
manner in the parental strain. In contrast, sigB activation by SAL was progressively more mitigated in the rsbU
and rsbV mutants. As predicted, SAL caused significant reductions in both alpha-toxin production and
fibrinogen and fibronectin binding in the parental strain. The extent of these reductions, compared with the
parent, was reduced in the rsb mutants (rsbV > rsbU), especially at low SAL concentrations. Since generation
of the free SigB protein usually requires a sequential rsbU-V-W-sigB activation cascade, the present phenotypic
and genotypic data suggest key roles for both rsbU and rsbV in SAL-mediated activation of sigB in strains with
a fully intact sigB operon.
The ability of Staphylococcus aureus to survive stress condi-
tions is attributable to activation of stress-response regulatory
elements, particularly sigma factor B (sigB) (10, 11). Such
stress conditions include extremes of temperature, pH, and
osmolarity, as well as nutrient limitations, ethanol exposures,
and oxygen depletion in vitro (10, 11). The response regulator
sigB can control a number of downstream gene promoters that
possess a SigB recognition motif (12). Thus, during in vitro
growth in routine laboratory medium, sigB activation can mod-
ulate the expression of the global regulator, sarA, by enhancing
activation of the sarA P3 promoter (4, 6). We recently showed
that salicylic acid (SAL), the major in vivo biometabolite of
aspirin in humans, down-modulates the virulence of S. aureus
in experimental infection models (e.g., infective endocarditis
[IE]) by mechanisms that are largely independent of the anti-
platelet effects of aspirin (17). These studies indicated that
SAL was a potent activator of the sigB operon (rsbU-V-W-sigB)
both in vitro and in vivo. In turn, such activation was associated
with a reduction in SarA protein expression and mitigation of
agr- and sarA-dependent gene expression (e.g., fnbA and hla)
(3, 6). The phenotypic consequences of these genotypic effects
were reduced production of alpha-toxin and reduced binding
to fibronectin and fibrinogen (17). Reductions in these pheno-
types have been demonstrated to be critically involved in de-
creased S. aureus virulence in experimental IE (17).
An interesting aspect of the above investigations was that
SAL could activate sigB in strains containing either an intact or
defective rsbU locus within the sigB operon, thus implicating
both rsbU-dependent and rsbU-independent pathways for ac-
tivation (17). The current study was designed to further exam-
ine the role of rsbU, rsbV, and rsbW in mediating the impact of
SAL on sigB activation as well as upon sigB-modulated down-
stream virulence phenotypes. For these investigations, we uti-
lized strategic single-knockout constructs within the sigB
operon of a sigB-intact parental strain.
MATERIALS AND METHODS
Bacterial strains and plasmids. The bacterial strains and plasmids used in this
study are listed in Table 1. FDA486 is an rsbU  S. aureus strain previously used
to study expression of fibrinogen-binding proteins and sigB-dependent transcrip-
tion of selected target genes (24). RN4220 is a restriction-deficient S. aureus host
strain used as the initial recipient for transformation of plasmids (22). Esche-
richia coli XL1-Blue was used for cloning isolated DNA fragments.
Allelic replacement in S. aureus strain FDA486. The construction of rsbU and
rsbV mutants in FDA486 has been described in a previous study (24). We also
constructed an rsbW mutant of FDA486. Briefly, a region upstream of rsbW was
amplified with the primers 5-GCTGGAATTCCGCCTGGATATATTTATC-3
and 5-TTCGCCCGGGGTTCCTTCATTAACATGC-3 (EcoRI and SmaI
sites, respectively, are underlined) and then digested with EcoRI and SmaI. The
fragment was cloned into the EcoRI-SmaI sites of the temperature-sensitive
shuttle vector pCL52.2 (24). A region downstream of rsbW was amplified with the
following primers with flanking PstI and HindIII restriction sites (underlined),
respectively: 5-TAAACTGCAGGAGCAGGTGCGAAATAAT-3 and 5-TGC
CAAGCTTTGTAATTTCTTAATTGCC-3. The downstream fragment was di-
gested with PstI and HindIII and cloned into the PstI-HindIII sites of pCL52.2,
already containing the upstream fragment. The ermC gene was excised from
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pALC552 and introduced into the BamHI-SalI site of pCL52.2 (24), thus result-
ing in divergent transcription of the ermC gene from the rest of the sigB operon.
The constructed plasmid was electroporated into S. aureus RN4220 to select for
tetracycline-resistant colonies (3 g/ml) at 32°C. The recombinant pCL52.2 was
then transduced from RN4220 into strain FDA486 with phage 11. Transduc-
tants were selected on tryptic soy agar plates containing tetracycline at 32°C. One
clone containing the plasmid was grown in 0.3 GL broth (0.3 M glycerol-lactate/
BHI broth) (21, 23a) with tetracycline (3 g ml1) and erythromycin (5 g ml1)
at 32°C overnight, followed by 12 h of growth in medium with erythromycin at
42°C, the nonpermissive temperature for pCL52.2 replication. The culture was
diluted 1:100 into fresh 0.3 GL broth and incubated at 32°C without antibiotics
for 12 h; this step was repeated several times. Erythromycin-resistant but tetra-
cycline-sensitive colonies were selected for further analysis. To validate the
authenticity of the rsbW mutant, we used a primer (5-ATGGTCTATTTCAAT
GGCAGTTAC-3) corresponding to bases 331 to 335 of the ermC gene (FASTA
search; GenBank accession no. Y17294) in combination with a primer down-
stream of the sigB gene (5-AATATCCTTCTTTAATTCCTCAGTA-3) to con-
firm replacement of rsbW with rsbW::ermC by PCR. The resultant PCR frag-
ment was sequenced with identical primers. As an additional confirmation,
chromosomal DNA from parental strain FDA486 and the rsbW deletion mutant
strains was digested with EcoRV and probed in Southern hybridization experi-
ments with labeled PCR fragments of individual genes within the sigB operon. To
confirm that the rsbU and rsbV mutations did not lead to polar mutations
downstream in the operon, we conducted Western blot analysis of cell extracts of
FDA486 and its isogenic rsbU, rsbV, and rsbW mutants with anti-SigB monoclo-
nal antibody 1D1 as previously described (6).
Gene expression studies and assay for sigB activation by SAL. The function of
the sigB operon depends on the generation of free SigB protein, i.e., upon the
release of SigB from the normally inactive RsbW-SigB complex. This release is
facilitated by the competitive binding of RsbW by the dephosphorylated form of
RsbV upon activation by RsbU (11, 14, 21). Since the total pool of the SigB
protein is relatively constant (free plus bound SigB), the extent of the level of
free SigB is typically assessed by quantifying expression of one or more sigB-
dependent promoters (6, 9). For this reason, we determined the expression of the
sigB-dependent sarA P3 and the alkaline shock protein (asp23) promoters by
green fluorescent protein (GFP) reporter and Northern blot analyses in the
presence or absence of SAL. The asp23 promoter has been previously used as a
faithful surrogate for sigB activation (9, 17).
(i) GFP reporter assays. To monitor sarA P3 promoter activation in the
presence or absence of SAL, we used a promoterless red-shifted variant of the
gfpuv gene (gfpuvr), as previously detailed (15). This gene was cloned downstream
of the sarA P3 promoter in plasmid pALC1484, which was then electroporated
into the parental strain FDA486, as well as into various rsb mutants described
above. The gfpuvr fusion constructs allow detection and quantification of the
upstream promoter activity by fluorometric techniques (28). All rsb mutant
constructs grew at the same rate as the wild-type parental strain. Also, the rsb
mutant constructs bearing the plasmid containing gfpuvr grew at similar rates in
the presence of chloramphenicol (10 g/ml). Moreover, ethidium bromide-
stained gels of plasmids among the wild-type strain and rsb mutant constructs
revealed similar intensities when equivalent numbers of bacterial cells were
analyzed. These latter two observations underscore the equivalence of plasmid
copy numbers in the parental strain and mutant constructs. To monitor sigB
activation of the sarA P3 promoter (a relatively weak promoter) in the presence
or absence of SAL, we utilized an FL600 microplate fluorescence reader (Bio-
Tek Instrument, Winooski, VT) with 485/516 nm filters. To monitor sigB acti-
vation of the asp23 promoter (a strong promoter) in the presence or absence of
SAL, we utilized a previously published, standard fluorometric assay (Turner
Fluorometer; Dubuque, IA) (28). As with the sarA P3 construct above, the asp23
promoter was cloned upstream of the gfpuvr gene on plasmid pALC1484 and
introduced into the FDA486 strain set as described. For the sarA P3 construct,
GFP expression was quantified at 0, 2, 12, and 28 h of growth at 37°C with
shaking (200 rpm). For the asp23 construct, aliquots were obtained at 0, 6, 16,
and 24 h. Extensive pilot studies had indicated that these distinct sampling times
provided the maximal separation in promoter expression profiles between un-
treated versus SAL-treated cells (data not shown). No antibiotics were included
in the growth medium for gfp constructs.
(ii) Northern blot hybridization. To verify the putative importance of rsbU in
activation of the sigB operon by SAL, we performed Northern blotting to mon-
itor sarA P3 and asp23 transcriptions. RNA samples were obtained during early
postexponential phase, at an optical density at 650 nm (OD650) nm of 1.7 (6 h
of growth), using an 18-mm borosilicate glass tube in a Spectronic 20 spectro-
photometer. Twenty micrograms of total cellular RNA from FDA486 and its
isogenic mutants (strains carrying rsbU, rsbV and rsbW mutations) were electro-
phoresed through a 1.5% agarose–0.66 M formaldehyde gel in running buffer (20
mM morpholinepropanesulfonic acid, 10 mM sodium acetate, 2 mM EDTA, pH
7.0). Blotting of RNA onto Hybond N membranes (Amersham, Arlington
Heights, IL) was performed with a Turbo-blotter alkaline transfer system
(Scheicher and Schuell, Inc., Keene, NH). The intensities of the 23S and 16S
rRNA bands stained by ethidium bromide were verified to be equivalent among
samples prior to transfer. A [32P]dCTP-labeled sarA fragment was used to detect
sarA transcript as described previously (2). We utilized specific primers (5-TA
GGTATTGGGTATATGAAAGA-3 and 5-TTGTCTTTCTTGGTTATTGTT
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Description or construction Source or reference
Strains
E. coli XL-1 Blue Highly transformable strain Stratagene
S. aureus
FDA486 Wild-type strain with intact rsbU gene 24
RN4220 Restriction-deficient derivate of 8325-4 22
ALC2128 rsbU mutant of FDA486 24
ALC2129 rsbV mutant of FDA486 24
ALC2130 rsbW mutant of FDA486 This study
FDA486 sarA P3-gfp FDA486 with sarA P3 promoter driving gfpuvr in pSK236 This study
ALC2128 sarA P3-gfp rsbU mutant with sarA P3 promoter driving gfpuvr in pSK236 This study
ALC2129 sarA P3-gfp rsbV mutant with sarA P3 promoter driving gfpuvr in pSK236 This study
ALC2130 sarA P3-gfp rsbW mutant with sarA P3 promoter driving gfpuvr in pSK236 This study
ALC2322 FDA486 with asp23 promoter driving gfpuvr in pSK236 17
ALC2128 asp23-gfp rsbU mutant with asp23 promoter driving gfpuvr in pSK236 This study
ALC2129 asp23-gfp rsbV mutant with asp23 promoter driving gfpuvr in pSK236 This study
ALC2130 asp23-gfp rsbW mutant with asp23 promoter driving gfpuvr in pSK236 This study
Plasmids
pCL52.2 Shuttle vector with temperature-sensitive origin of replication for S. aureus 19
pALC552 pBluescript containing the ermC gene 24
prsbW This study
pSK236 Shuttle vector containing pUC19 cloned into the HindIII site of pC194 20
pALC1484 pSK236 containing gfpuvr
pALC1672 pSK236 containing sarA P3::gfpuvr This study
pALC2201 pSK236 containing asp23::gfpuvr This study
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T-3) to amplify a 624-bp fragment to be used as a probe to detect asp23
expression. All the probes were radiolabeled by the random primer method
(Ready-To-Go labeling kit; Amersham). The blots were hybridized under high-
stringency conditions, washed, and autoradiographed as previously described (7).
Phenotypic studies. (i) Fibrinogen and fibronectin binding assays. We have
previously reported that SAL mitigates S. aureus binding to solid-phase fibrino-
gen and fibronectin biomatrices in vitro (17). To assess the effects of various rsb
mutations on this SAL-mediated phenotype, the parent and all mutant constructs
were grown to postexponential phase for maximal sigB expression (9) in the
presence or absence of SAL (at 25 or 50 g/ml). Following pelleting, washing,
and bovine serum albumin blocking steps (17), 5  103 CFU of each construct
were added to six-well polystyrene plates precoated with 50 g/ml of either
fibrinogen or fibronectin. Prior to the addition, the bacterial inoculum was briefly
sonicated to ensure singlet cells and then allowed to bind to the above bioma-
trices for 1 h at 37°C on a rotating platform. After unbound cells were removed
by three washes with phosphate-buffered saline, 2 ml of tryptic soy agar was
overlaid in all wells. Plates were incubated at 37°C for 24 h, when all visible
colonies were counted. Bacterial binding was quantified as the percentage of the
initial inoculum bound in the presence or absence of SAL. Data were calculated
as the means (	 standard deviation [SD]) of three independent runs and ex-
pressed as the mean percent reductions of fibrinogen or fibronectin binding
under various assay conditions.
(ii) Alpha-toxin activity in the presence of SAL. To monitor the impact of SAL
on the production of alpha-toxin in the parental strain versus various rsb mutants,
we employed a well-established phenotypic assay in which the ability of alpha-
toxin to lyse rabbit erythrocytes was measured (17). S. aureus strains were grown
at 37°C in tryptic soy broth (control cells) or in medium containing 25 or 50 g/ml
SAL for 18 h to stationary phase on a rotary shaker. After cells were pelleted at
5,000  g for 10 min, the number of cells in each tube was standardized by
spectrophotometry, and aliquots of serial dilutions of culture supernatants were
added to a 1% suspension of washed rabbit erythrocytes in 0.01 M phosphate-
buffered saline (pH 7.2) containing 0.1% bovine serum albumin. Purified alpha-
toxin (1 g/ml; Toxin Technology, Sarasota, FL) was used as a positive control.
Data were expressed as mean units of hemolytic activity (	 SD) per ml of culture
supernatant from six separate runs. The hemolytic units were defined as the
reciprocal of the highest dilution of the culture supernatant causing 50%
erythrocyte lysis as measured by optical densitometry (17).
Statistics. Continuous data were statistically analyzed by a Kruskal-Wallis
analysis of variance, with corrections for multiple comparisons where appropri-
ate. A P value of 
0.05 was considered significant.
RESULTS
The impact of rsbU, rsbV, and rsbW mutations on SigB ex-
pression. The transcription of sigB has been shown to be de-
pendent on at least two promoters, one originating upstream
of rsbU and another upstream of rsbV. A third promoter fur-
ther upstream of rsbU has also been described (23) (Fig. 1A).
To ensure that our mutation on rsbU and rsbV did not impact
on SigB expression, we probed an immunoblot containing
equivalent amounts of cell extracts from overnight cultures of
the mutants with the anti-SigB monoclonal antibody 1D1. As
the replacement ermC gene is transcribed divergently from the
rest of the sigB operon, inactivation of rsbU and rsbV did not
lead to null expression of SigB (Fig. 1B). Indeed, the SigB
protein levels were clearly demonstrable, albeit at lower levels
in the rsbU and rsbV mutants than in the parental strain
FDA486 (24). This is consistent with the observation that rsbU
and rsbV are driven by separate promoters and that activation
of rsbU can occur independently of rsbV (24). The expression
of SigB, encoded by the last gene in the operon, in both
mutants also suggests that any potential polar effect as a result
of the rsbU and rsbV mutations is probably minimal. We also
examined SigB expression in the rsbW mutant. Similar to the
sigB mutant, the rsbW mutant did not express any SigB as
detected by immunoblotting; this finding was expected because
the expression of RsbW and SigB are translationally coupled
(17, 27).
Induction of sarA P3 activity by SAL. In pilot screening
studies, we sought to establish a single effective SAL concen-
tration range to utilize in the detailed phenotypic and geno-
typic investigations. We thus exposed the parental strain to a
range of SAL concentrations (0 to 100 g/ml) encompassing
both clinically achievable human serum concentrations as well
as SAL concentrations previously documented to activate sigB
expression (17). Using sarA P3 promoter activation as a sur-
rogate marker for sigB expression, the lowest SAL concentra-
tion that clearly increased sigB expression compared to un-
treated cells was 50 g/ml (Fig. 2). We subsequently used the
range of 25 to 50 g/ml of SAL for the remaining phenotypic
and genotypic studies. SAL-induced sarA P3 activation in this
assay was apparent by 10 h of growth, reflecting both the
late-logarithmic-phase maxima of this promoter as well as the
time required for maturation of the GFP (13).
We then compared the relative, time-dependent expression
of the sarA P3 promoter, using GFP reporter assays in the
presence or absence of SAL (Fig. 3). Early in log-phase
growth, neither the parent nor any of the rsb mutants exhibited
substantial increases in sarA P3 promoter activity in the pres-
ence or absence of SAL. In contrast, at postexponential phase
(12 h), the parental strain, but not the rsbU, V, or W mutants,
exhibited increases in sarA P3 expression in the presence of
SAL, although this difference (3.5-fold) did not reach statis-
FIG. 1. The effect of rsbU and rsbV mutations on SigB expression in
the FDA486 background. (A) Organization of the sigB operon in S.
aureus. There are two well-described transcripts, one originating from
the A promoter upstream of rsbU and the other from the B promoter
upstream of rsbV. A third 3.6-kb transcript was recently described by
Senn et al. (25). (B) Equivalent amounts of cell extracts (50 g each)
from FDA486 and its isogenic mutants were immunoblotted onto
nitrocellulose. The blot was then probed with anti-SigB monoclonal
antibody 1D1 at a 1:2,000 dilution. The protein band was then detected
with goat anti-mouse antibody conjugated to alkaline phosphatase and
developing substrate as previously described (6). We also examined
expression of SigB in rsbW and sigB mutants of FDA486. In both cases,
no SigB protein expression was detected. These immunoblot data have
been previously published by one of our laboratories (24).
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tical significance. At 28 h of growth (late stationary phase), the
impact of SAL on parental strain FDA486 expression of sarA
P3 was more pronounced than at 12 h, with an observed 7.5-
fold increase compared to uninduced cells (P 
 0.05). Inter-
estingly, the upregulation in sarA P3 expression by SAL at 28 h
was higher in the rsbU mutant than in the rsbV and rsbW
mutants. This pattern of data shows that augmentation of sigB
activity due to SAL (albeit relatively small) can still occur with
an rsbU mutant at late stationary phase. To confirm these
observations, we conducted Northern analyses with a sarA
probe to ascertain sarA P3 transcription. At stationary growth
phase (Fig. 4A) and also at late exponential phase (not shown),
the expression level of the sarA P3 transcript was substantially
increased in the parental strain with SAL exposure compared
to the uninduced control (2,656 versus 1,088 densitometry
units, using SigmaGel software) (Fig. 4A). Interestingly, the
rsbU mutant was also able to modestly increase sarA P3 tran-
scription in the presence of SAL (2,069 versus 1,724 densitom-
FIG. 2. Effect of SAL at various drug concentrations upon sarA P3 promoter activity. Expression of gfp driven by the sarA P3 promoter was
measured during the growth cycle, and fluorescence values were expressed as total GFP fluorescence/OD650 to minimize variations in fluorescence
due to differing cell densities. These data represent the mean of three independent runs.
FIG. 3. Effect of SAL (50 g/ml) on sarA P3 promoter activation in the FDA486 parental strains versus the corresponding rsbU, rsbV, and rsbW
mutants. The percent differences were calculated by the following formula: [(fluorescence with SAL/fluorescence without SAL)  1.0]  100.
Results are the means (	 SD) of triplicates from a representative experiment that was repeated thee times.
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etry units in the uninduced control). As an additional marker
for sigB activation, we evaluated asp23 transcription in the
parent strain FDA486 and its isogenic rsbU mutant. As shown
in Fig. 4B and mirroring data in Fig. 4A, the parental strain
displayed an increase in asp23 transcription with SAL exposure
compared to the uninduced control, while the increase in the
rsbU mutant was more modest.
We next compared the relative, time-dependent expression
from the asp23 promoter, using GFP as a reporter, in the
presence or absence of SAL (Fig. 5). Similar to the data for
sarA P3, the parental strain exhibited a substantial increase in
asp23 expression in the presence of SAL versus uninduced
control over the 28-h growth cycle (range, mean percentage
change of 1 to 28% at 25 g/ml versus uninduced controls
[data not shown] and 36 to 66% at 50 g/ml). These differences
reached statistical significance at the 28-h time point of SAL
exposure (P 
 0.05 versus both uninduced parental cells and
induced rsb mutant cells). In contrast, asp23 expression in the
three rsb mutants was only modestly induced by SAL at the
same drug concentrations. However, these differences (versus
uninduced cells) did not reach statistical significance for the
mutants.
Phenotypic assays. (i) Fibrinogen and fibronectin binding.
In previous studies, we have shown that SAL can reduce the
fibrinogen- and fibronectin-binding capacity of wild-type S.
aureus cells (17). Interestingly, baseline fibrinogen binding, as
a reflection of intrinsic bacterial adhesion capacity, was similar
between untreated parental cells and the three rsb mutants
(range, 4.2 to 4.9% of the initial inoculum) (Table 2). Parallel
FIG. 4. Transcription of the sarA P3 (A) and asp23 (B) promoter in
response to SAL (50 g/ml) by Northern blotting of S. aureus FDA486
(parental) and its corresponding rsbU deletion mutants at the postex-
ponential phase of bacterial growth. Lane 1, wild-type strain FDA486;
lane 2, wild-type strain FDA486 with SAL; lane 3, rsbU mutant; lane 4,
rsbU mutant with SAL. The figures underneath the blots indicate
equivalent loading as reflected by similar ethidium bromide staining of
the 16S and 23S rRNA bands.
FIG. 5. Effect of SAL (50 g/ml) on asp23 promoter activation in the FDA486 parental strain versus the corresponding rsbU, rsbV, and rsbW
mutants. The percent differences were calculated by the following formula: [(fluorescence with SAL/fluorescence without SAL)  1.0]  100.
Results are the means (	 SD) of triplicates from a representative experiment that was repeated thee times.
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data were also observed for fibronectin binding, showing sim-
ilar binding among all constructs (range, 3.8 to 4.8% of initial
inoculum) (Table 2). Upon SAL exposure, the parental cells
showed substantial reductions in binding to fibrinogen in a
dose-dependent manner, with more reduction at 50 g/ml
(P 
 0.05 versus control cells) than at 25 g/ml. Similarly, the
SAL-mediated reduction in fibronectin binding for parental
cells was greater at 50 g/ml SAL than the untreated control
(P 
 0.05) (Table 2). For both assays, the reductions in ligand-
binding capacity seen in the parental strain were blunted in all
rsb mutants. Of note, there was somewhat greater dampening
of the SAL impact in the rsbV (versus uninduced cells) com-
pared to the rsbU mutant at 25 g/ml SAL (but not at 50
g/ml), although this did not reach statistical significance.
(ii) Alpha-toxin assays. In an earlier study (17), we found
that preexposure of wild-type S. aureus cells to SAL reduced
their capacity to express alpha-toxin, presumably by up-regu-
lating sigB activity. To investigate the role of specific genes
within the sigB operon in mediating this effect, rsb mutants
were assayed for hemolytic activity (attributable to alpha-
toxin) following SAL exposures. As expected, supernatants
from stationary-phase parental cells treated with SAL exhib-
ited a significantly diminished capacity to lyse erythrocytes,
compared to supernatants from untreated cells, in a dose-
dependent manner (35 to 50% reductions; P 
 0.05 versus
untreated control cells) (Table 3). Of interest, the stationary-
phase supernatants from all untreated rsb mutant cells exhib-
ited higher baseline hemolytic activity than parental cells, with
the rsbV and rsbW mutants showing a more prominent increase
than the rsbU mutant. Remarkably, the capacity of SAL to
reduce hemolytic activity, as seen in parental cells, was blunted
in the rsbU mutant. The rsbV and rsbW mutants also displayed
minimal decreases in hemolytic titer in the presence of 25 or 50
g/ml of SAL compared with nontreated controls. For the rsbU
mutant, the hemolytic titer at 50 g/ml of SAL was equal to the
parental strain without SAL exposure.
DISCUSSION
The sigB operon of S. aureus represents a global regulatory
system that enables the organism to deal with environmental
stresses. However, it differs from the well-characterized sigB
operon of Bacillus subtilis in that it is smaller (four genes versus
eight genes) and lacks distinct environmental and energy-sens-
ing modules (27) (Fig. 1A). The sigB operon of S. aureus
consists of a putative sensor (rsbU) which responds to a broad
range of microenvironmental cues via autophosphorylation to
activate the next gene in this operon (rsbV). Phosphorylated
RsbU acts as a phosphatase (or an anti-anti-sigma factor) to
dephosphorylate RsbV. Dephosphorylated RsbV binds com-
petitively to the anti-sigma factor, RsbW, thus displacing the
normally inhibitory RsbW from the RsbW-SigB complex (21).
The collective result of this activation cascade is the release of
free SigB to activate genes with a SigB recognition motif within
their promoter region (e.g., sarA P3 and asp23) (3) via recruit-
ment of RNA polymerase.
Likely related to its role in countering environmental
stresses, the sigB operon has been shown to be intimately
involved in biofilm formation (1), as well as in the regulation of
virulence factors. As an example, the activation of the sarA P3
promoter impacts the expression of sarA-dependent structural
genes, including the genes for alpha-toxin (hla), V8 protease
(sspA), and fibronectin-binding proteins (e.g., fnbA) (3). SigB
may also repress expression of the two-component regulatory
system, saeRS, which itself positively regulates hla and fnbA
expression (26). Importantly, during in vitro growth, sigB is
activated at early stationary growth phase, corresponding to its
activation of the sarA P3 promoter. Since SarA production is
the net result of activation of the three sarA promoters (sarA
P1, P2, and P3), sarA P3 activation normally leads to enhanced
SarA production. However, Karlsson et al. (16) have shown
recent data suggesting that clinical S. aureus strains differ sub-
stantially in intrinsic “tone levels” of sigB and SigB-dependent
gene expression. This concept was exemplified by the strain-
to-strain variability in the production of V8 protease (a SigB-
SarA repressible event) (16). Similarly, we have shown that
sigB can be exogenously stimulated by SAL to a high “tone
level,” resulting in augmented transcription from the sarA P3
promoter. Contrary to growth phase-related effects on SarA
expression (i.e., upregulation), hyperactivation of sigB due to
exogenous SAL leads to reductions in net sarA activation
(manifested by both reduced SarA protein levels and enhanced
V8 protease and lipase production) (16, 17). The mecha-
nism(s) by which excess sarA P3 activation by SAL mitigates
overall sarA expression is not understood but may involve
promoter occlusion of the proximal, but more prominent, sarA
P1 promoter. Alternatively, a direct effect of SAL on the sarA
promoter complex cannot be ruled out.
We previously demonstrated that the major biometabolite of
aspirin, SAL, exerts potent antivirulence effects in vitro and in
vivo against a number of well-characterized S. aureus strains,
TABLE 3. -Toxin hemolytic activity in S. aureus strain FDA486
and its isogenic mutants in the presence or absence of SAL
SAL concn
(g/ml)






Control 658 	 38 825 	 69 983 	 104 992 	 38
25 383 	 52b 700 	 71 933 	 58 917 	 41
50 333 	 41b 658 	 31 867 	 29 883 	 26
a Results are expressed in hemolytic units. See text for details.
b P 
 0.05 versus untreated control cells.
TABLE 2. Adhesion of S. aureus strain FDA486 and corresponding
rsbU, rsbV, and rsbW mutants to immobilized fibrinogen and
fibronectin in the presence or absence of SAL
Strain or
mutant





25 g/ml 50 g/ml 25 g/ml 50 g/ml
FDA486 4.2 	 1.1 25.40 47.10c 3.8 	 1.1 20.90 45.50c
rsbU mutant 4.5 	 1.2 14.20 23.30 4.8 	 1.3 15.40 24.30
rsbV mutant 4.5 	 1.1 8.90 22.10 4.8 	 1.0 13.90 25.30
rsbW mutant 4.9 	 0.8 11.80 21.10 4.5 	 1.4 8.30 13.10
a Percent binding of initial inoculum to ligand in the absence of SAL.
b Mean percent reduction in binding comparing SAL-treated versus untreated
(control) S. aureus cells. These data are derived from the means of three inde-
pendent runs and are expressed as mean percent reductions of fibrinogen or
fibronectin binding under various assay conditions.
c P 
 0.05 versus untreated control cells.
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including RN6390, SH1000, ISP479, COL, and Newman (17).
These antivirulence effects include reduction in binding to a
variety of matrix ligands involved in tissue colonization by S.
aureus (i.e., fibrinogen, fibronectin, and fibrin), reduction in
binding to endothelial cells and platelets (18), and reduction in
alpha-toxin production (17). All these phenotypic traits have
been linked to the virulence of S. aureus in endovascular and
other infection models (5). These in vitro phenotypic effects
were mirrored in vivo in experimental endocarditis (IE) mod-
els as exemplified by the reduced capacity of SAL-treated S.
aureus cells to bind to sterile aortic valve vegetations in vivo
(17). Treatment of animals with established S. aureus IE by
aspirin or SAL also mitigated virulence, as manifested by re-
ductions in bacterial densities in cardiac vegetations and kid-
neys, decreases in vegetation size and weight, and prevention
of embolic renal infarcts (17, 18). Importantly, the fact that
SAL (which is devoid of antiplatelet activities) demonstrated
antivirulence properties virtually identical to those of aspirin
argued against the idea that the antiplatelet property of aspirin
is the principal abating factor and, instead, indicated the pos-
sibility that an antibacterial pathway is at work. This hypothesis
was validated by our genetic analyses in vitro and in vivo,
clearly showing that activation of sigB is a critical event in
initiating the antivirulence properties of aspirin and SAL (17).
This mechanism then leads to down-modulation of global
regulons downstream of sigB (e.g., sarA and agr), as well as of
key structural genes involved in matrix ligand binding and
alpha-toxin production (3). Of note, a recent investigation by
Entenza et al. (8) has confirmed that sigB-hyperexpressing
strains of S. aureus exhibit reduced virulence during well-es-
tablished stages of experimental endocarditis compared to
wild-type strains.
Despite the unambiguous role of sigB activation by aspirin or
SAL in antivirulence properties, the contribution of each gene
within the sigB operon (i.e., rsbU, rsbV, or rsbW) to this impact
is not known. As sigB activation by aspirin or SAL occurred in
strains RN6390 and ISP479 (rsbU-deficient lineage strains of
8325-4) (14) as well as in the rsbU-intact strains SH1000, COL,
and Newman, this suggested that activation of sigB by these
compounds could proceed via both rsbU-dependent and rsbU-
independent pathways.
The current study was designed to establish the relative roles
of individual genes within the sigB operon in mediating the in
vitro activation by SAL and in impacting two representative
phenotypes (ligand binding and alpha-toxin production). Sev-
eral interesting findings emerged from this investigation. (i) In
parental strain FDA486 (with an intact sigB operon), deletion
of rsbU eliminated a major portion of the capability of the
strain to respond to SAL, corresponding to a lesser capacity to
activate sigB in the rsbU mutant. This relationship was evi-
denced by a much lower level of sigB-dependent promoter
activation (e.g., sarA P3) in the rsbU mutant as confirmed by
Northern blotting and transcriptional fusions. (ii) The influ-
ences of SAL on sigB activation were concentration dependent,
and the differences between untreated cells and SAL-treated
cells were greatest during stationary phases of growth (when
sigB expression is maximal). (iii) Our data suggested that both
rsbU and rsbV can be targets for SAL. This notion was sup-
ported by a hierarchy in the reduction of ligand-binding capac-
ity between the parent and these two latter mutants at 25 g/ml
of SAL (Table 2). This hierarchy was recapitulated in the
reduction in hemolytic titers (Table 3) at both SAL concentra-
tions (i.e., parent rsbU mutant rsbV mutant). Based on our
previous studies, we recognized that even in the rsbU mutant
(the putative stress-sensing locus within sigB), sigB could still
be partially activated by energy-dependent stresses (24). This
observation and the data from the present study underscore
the notion that sigB can be activated by rsbU-dependent and
rsbV-dependent pathways. (iv) SigB is normally a repressor of
alpha-toxin gene (hla) expression; thus, deletion of genes
within the sigB operon normally results in alpha-toxin hyper-
expression (6, 24), as confirmed in the rsbU and rsbV mutants
in the current investigation. Because rsbW and sigB are trans-
lationally coupled (21), the rsbW mutant behaves essentially
like a sigB mutant. Whether SigB represses alpha-toxin pro-
duction in the presence of SAL via inhibition of sarA, agr,
and/or sae remains to be defined. (v) As noted above, SAL
exposure in parental strain FDA486 resulted in a reduction in
ligand-binding phenotypes; this effect was blunted in the rsbU
mutant and more so in the rsbV and rsbW mutants at 25 g/ml.
The basis for the disappearance of this differential effect be-
tween rsbU and rsbV mutants at 50 g/ml of SAL is not im-
mediately evident. It is plausible that SAL at higher concen-
trations may affect the baseline phosphorylation of RsbV.
In summary, we have confirmed that SAL exerts substantial
effects on phenotypes involved in endovascular virulence via
activation of the sigB operon; interruption of the sigB gene
cascade by mutating loci within the operon will blunt this
response. Further, the phenotypic effects of SAL appear to
proceed via both rsbU-dependent and rsbV-dependent path-
ways. Whether SAL has direct influences upon downstream
structural genes (e.g., hla) or if SAL can upregulate pathways
outside of sigB to impact the above phenotypes remains to be
defined.
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